In narcolepsy, targeting specific nerve cells involved in sleep–wake transitions may offer a way to address excessive daytime sleepiness and cataplexy, a sudden loss of muscle tone that happens while a patient remains conscious, according to a study in mice. Targeting these nerve cells could offer “a novel therapeutic…
News
The U.S. Food and Drug Administration (FDA) has granted fast track designation to Lu AH69593, an experimental oral therapy Lundbeck is developing to treat narcolepsy. The FDA awards this designation to help speed the development of medicines designed to treat serious disorders and fill unmet medical needs. With…
Managing narcolepsy works best when medication is paired with routine sleep habits, healthy lifestyle changes, and personal support systems, with some people controlling symptoms well using little or no medication, a new study shows. The qualitative study from Slovakia highlights how behavioral strategies, psychological coping, and support from family…
Daytime wakefulness and certain patterns of nighttime sleep fragmentation may help distinguish adults with narcolepsy type 1 (NT1) from those with type 2 (NT2), according to an analysis of participants who were not taking narcolepsy medications while enrolled in one of two eight-week clinical trials. People with NT2 showed…
The U.S. Food and Drug Administration (FDA) has agreed to review an application seeking approval of Axsome Therapeutics‘ experimental therapy AXS-12 (reboxetine) to treat cataplexy — a sudden drop in muscle tone — in people with narcolepsy. The company said it expects the FDA to issue a decision…
Long-term treatment with the experimental oral therapy alixorexton safely improved wakefulness, eased fatigue, and boosted cognition for people with narcolepsy in clinical trials, according to interim data announced by alixorexton’s developer, Alkermes. “These long-term results represent a significant contribution to our understanding of alixorexton as a potential new…
Editor’s note: This story includes discussion of suicide. If you or someone you know needs help, the national suicide and crisis lifeline in the U.S. is available by calling or texting 988. There is also an online chat at 988lifeline.org. Internationally, find a suicide prevention helpline…
Tooth loss is associated with daytime sleepiness and snoring, and may also be linked to excessive sleep duration, according to a large national study in Chile. The study analyzed data from more than 5,000 participants included in the Chilean National Health Survey, and suggested that people with fewer or no…
A previously healthy 42-year-old woman in Europe developed type 1 narcolepsy with cataplexy — sudden episodes of muscle weakness triggered by emotions — after COVID-19, according to a new report by researchers urging possible checks for sleep disorders in patients…
People with narcolepsy or idiopathic hypersomnia (IH) frequently have cardiovascular, metabolic, and kidney-related conditions that may increase their vulnerability to the effects of sodium exposure from diet or medications, according to a large U.S. study. Researchers found that almost 70% of people with narcolepsy or IH had at least…
Recent Posts
- Getting my dad’s perspective on how I’m living with narcolepsy
- Study tracks narcolepsy incidence, healthcare costs in France
- Exploratory study IDs protein that may help in diagnosing narcolepsy
- NapChat helped me find my voice as a narcolepsy advocate
- Daytime sleep patterns may aid narcolepsy diagnosis, study finds